California State Teachers Retirement System Has $4.63 Million Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

California State Teachers Retirement System raised its stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 10.7% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 391,703 shares of the company's stock after purchasing an additional 37,982 shares during the period. California State Teachers Retirement System owned 0.05% of Roivant Sciences worth $4,634,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. FMR LLC lifted its position in Roivant Sciences by 0.3% in the 4th quarter. FMR LLC now owns 49,301,583 shares of the company's stock valued at $583,238,000 after purchasing an additional 156,527 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Roivant Sciences by 5.8% in the fourth quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company's stock valued at $521,553,000 after buying an additional 2,404,232 shares in the last quarter. Patient Square Capital LP lifted its holdings in shares of Roivant Sciences by 2.1% during the fourth quarter. Patient Square Capital LP now owns 12,480,000 shares of the company's stock valued at $147,638,000 after purchasing an additional 251,535 shares during the last quarter. Two Seas Capital LP boosted its holdings in shares of Roivant Sciences by 4.6% in the fourth quarter. Two Seas Capital LP now owns 10,167,807 shares of the company's stock worth $120,285,000 after buying an additional 442,914 shares during the period. Finally, Invesco Ltd. boosted its stake in Roivant Sciences by 49.7% in the 4th quarter. Invesco Ltd. now owns 9,515,058 shares of the company's stock worth $112,563,000 after purchasing an additional 3,159,603 shares during the period. Institutional investors own 64.76% of the company's stock.

Analyst Ratings Changes

ROIV has been the topic of a number of research reports. Cantor Fitzgerald upgraded Roivant Sciences to a "strong-buy" rating in a report on Tuesday, March 4th. HC Wainwright restated a "buy" rating and set a $18.00 price target on shares of Roivant Sciences in a report on Wednesday, May 28th.

Roivant Sciences Price Performance

ROIV traded down $0.01 during midday trading on Thursday, hitting $11.20. 5,918,433 shares of the company's stock traded hands, compared to its average volume of 5,554,778. The company has a market cap of $7.99 billion, a PE ratio of -74.66 and a beta of 1.23. Roivant Sciences Ltd. has a one year low of $8.73 and a one year high of $13.06. The stock's fifty day simple moving average is $10.59 and its 200-day simple moving average is $11.02.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last announced its quarterly earnings results on Thursday, May 29th. The company reported ($0.31) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.15). The company had revenue of $7.57 million during the quarter, compared to analyst estimates of $62.17 million. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. During the same period in the prior year, the firm earned ($0.23) EPS. On average, research analysts expect that Roivant Sciences Ltd. will post -0.92 EPS for the current year.

Insider Buying and Selling at Roivant Sciences

In other news, major shareholder Vivek Ramaswamy sold 273,959 shares of Roivant Sciences stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $11.47, for a total value of $3,142,309.73. Following the transaction, the insider now directly owns 39,799,611 shares in the company, valued at approximately $456,501,538.17. The trade was a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Eric Venker sold 315,522 shares of the stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $11.06, for a total value of $3,489,673.32. Following the sale, the chief operating officer now owns 959,457 shares of the company's stock, valued at approximately $10,611,594.42. The trade was a 24.75% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 2,223,959 shares of company stock worth $24,604,977 over the last 90 days. Insiders own 7.90% of the company's stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.